Navigation Links
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Date:10/12/2009

ROCKVILLE, Md., Oct. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S. anti-psychotic market is approximately $14 billion.

Under the terms of the agreement, which amended and restated a prior agreement among the parties, Novartis will have exclusive commercialization rights to Fanapt(TM) for the U.S. and Canada. Novartis will be responsible for the further clinical development activities in these territories, including the development and commercialization of a long-acting injectable (or depot) formulation of Fanapt(TM). Vanda will retain rights to commercialize Fanapt(TM) oral and depot formulations outside the U.S. and Canada. At Novartis' option, the parties will enter into good faith discussions relating to an agreement for the co-commercialization of Fanapt(TM) outside of the U.S. and Canada or, alternatively, Novartis will receive a royalty on net sales.

Under the agreement, Vanda will receive an upfront payment of $200 million and will be eligible for additional payments totaling up to $265 million upon the achievement of certain development and commercial milestones for Fanapt(TM) in the U.S. and Canada. Vanda will also receive royalties on the U.S. and Canadian net sales of Fanapt(TM). The consummation of the transaction is subject to the receipt of customary regulatory approvals, which are expected by the end of 2009.

"I am very excited about our agreement with Novartis, as we now have one
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Vanda Pharmaceuticals Provides Update on Iloperidone
4. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
5. Vanda Presents Phase III Iloperidone Efficacy Data
6. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
7. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
8. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
9. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
11. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the addition of the ... to their offering. This report analyzes the ... following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... Elbit Imaging Ltd. ("EI" or ... today that Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: ... holds approximately 86% of the voting power, announced that ... Elbit Medical holds approximately 30.8% of the voting power ... shareholders (including Elbit Medical), signed Option and Investment Agreements ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3
... to the FDA, LAUSANNE, Switzerland, November ... development specialist that,focuses on serious medical conditions ... its Canadian affiliate, filed its Complete,Response to ... States (U.S.),Food and Drug Administration (FDA) for ...
... ANTIPOLIS, France, November 4 NicOx,S.A. (Euronext Paris: ... patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the ... of escalating,doses of naproxcinod and naproxen in osteoarthritis ... was the mean 24-hour,ambulatory systolic blood pressure (SBP) ...
Cached Medicine Technology:Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 2Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 2NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 4
(Date:8/19/2014)... August 20, 2014 Top10BestSEOHosting.com has ... JustHost are the recommended suppliers for the webmasters ... hosting products. , According to the senior spokesman ... the most affordable hosting products on the market ... offer a variety of online deals when service ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... August 19, 2014 Horizon Blue Cross Blue ... Morgan Hoffmann are once again teaming up during The ... cause through a Walking Challenge, and Horizon BCBSNJ will be ... a course challenge of their own. , Horizon BCBSNJ, the ... is making a $5,000 donation to the New Jersey Golf ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
Breaking Medicine News(10 mins):Health News:Fatcow Awarded As One of the Best Web Hosting Suppliers at Top10bestseohosting.com 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3
... today that it has dosed its first patient in ... ALT-2074, its lead glutathione peroxidase mimetic, in diabetic ... at high risk for cardiovascular complications. , ... ability to lower inflammatory cardiovascular biomarkers in patients with ...
... (JCVI) today announced the results of work on genome ... bacteria into another type dictated by the transplanted chromosome. ... journal Science, by JCVI's Carole Lartigue, Ph.D. and colleagues, ... bacterial species, Mycoplasma capricolum into another, Mycoplasma mycoides Large ...
... Businesses that offer customers shisha water pipes to smoke tobacco ... smoking ban that comes into force in England on Sunday. ... the water pipes are variously called, dozens of restaurants will ... see their sole activity disappear. ,"It's a disaster, ...
... name, one might rhetorically ask. But Malaccan state authorities have ... after their region. And now the virus will carry some ... announced last week they discovered a new virus likely carried ... called it the Melaka Virus, using the name of the ...
... with most other developing countries, plastic bags have become a terrible ... to be spiraling out of control, the government has announced a ... Uganda they are called buveera , and they are everywhere. ... organized dump like the one at Chitezi in Ugandan capital Kampala. ...
... found that nonsmoking restaurant and bar employees absorb a ... in places where they had to breathe tobacco smoke ... in the body only as a result of using ... the Multnomah County Health Department and Oregon Department of ...
Cached Medicine News:Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2Health News:Uganda Bans Plastic Bags, Still a Tough Battle Lies Ahead 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: